Literature DB >> 21044089

A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells.

C Berger1, M Berger, D Anderson, S R Riddell.   

Abstract

BACKGROUND: Adoptive immunotherapy with antigen-specific effector T-cell (T(E) ) clones is often limited by poor survival of the transferred cells. We describe here a Macaca nemestrina model for studying transfer of T-cell immunity.
METHODS: We derived, expanded, and genetically marked CMV-specific CD8(+) T(E) clones with surface markers expressed on B cells. T(E) cells were adoptively transferred, and toxicity, persistence, retention of introduced cell-surface markers, and phenotype of the persisting T cells were evaluated.
RESULTS: CD8(+) T(E) clones were efficiently isolated from distinct memory precursors and gene-marking with CD19 or CD20 permitted in vivo tracking by quantitative PCR. CD19 was a more stable surface marker for tracking cells in vivo and was used to re-isolate cells for functional analysis. Clonally derived CD8(+) T(E) cells differentiated in vivo to phenotypically and functionally heterogeneous memory T-cell subsets.
CONCLUSIONS: These studies demonstrate the utility of Macaca nemestrina for establishing principles for T-cell therapeutics applicable to humans.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044089      PMCID: PMC3048898          DOI: 10.1111/j.1600-0684.2010.00451.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  52 in total

1.  Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.

Authors:  Carolina Berger; C Anthony Blau; Meei-Li Huang; John D Iuliucci; David C Dalgarno; Joëlle Gaschet; Shelly Heimfeld; Tim Clackson; Stanley R Riddell
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

2.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

Authors:  Karl S Peggs; Stephanie Verfuerth; Arnold Pizzey; Naeem Khan; Malcolm Guiver; Paul A Moss; Stephen Mackinnon
Journal:  Lancet       Date:  2003-10-25       Impact factor: 79.321

3.  Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection.

Authors:  Thomas J Manley; Lisa Luy; Thomas Jones; Michael Boeckh; Helen Mutimer; Stanley R Riddell
Journal:  Blood       Date:  2004-03-23       Impact factor: 22.113

4.  Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1).

Authors:  T F Tedder; G Klejman; S F Schlossman; H Saito
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

5.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

6.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

Authors:  S R Riddell; M Rabin; A P Geballe; W J Britt; P D Greenberg
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

Review 7.  Of mice and not men: differences between mouse and human immunology.

Authors:  Javier Mestas; Christopher C W Hughes
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

8.  Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis.

Authors:  Marta Serafini; Martin Bonamino; José Golay; Martino Introna
Journal:  Haematologica       Date:  2004-01       Impact factor: 9.941

Review 9.  Central memory and effector memory T cell subsets: function, generation, and maintenance.

Authors:  Federica Sallusto; Jens Geginat; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  Retroviral vectors for high-level transgene expression in T lymphocytes.

Authors:  Boris Engels; Hakan Cam; Thomas Schüler; Stefano Indraccolo; Monika Gladow; Christopher Baum; Thomas Blankenstein; Wolfgang Uckert
Journal:  Hum Gene Ther       Date:  2003-08-10       Impact factor: 5.695

View more
  13 in total

1.  Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection.

Authors:  Christopher W Peterson; Patrick Younan; Patricia S Polacino; Nicholas J Maurice; Hannah W Miller; Martin Prlic; Keith R Jerome; Ann E Woolfrey; Shiu-Lok Hu; Hans-Peter Kiem
Journal:  J Med Primatol       Date:  2013-10       Impact factor: 0.667

Review 2.  CMV-specific immune reconstitution following allogeneic stem cell transplantation.

Authors:  Emily Blyth; Barbara Withers; Leighton Clancy; David Gottlieb
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

Review 3.  Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.

Authors:  Cameron J Turtle; Stanley R Riddell
Journal:  Curr Opin Immunol       Date:  2011-01-14       Impact factor: 7.486

4.  Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Authors:  Carolina Berger; Daniel Sommermeyer; Michael Hudecek; Michael Berger; Ashwini Balakrishnan; Paulina J Paszkiewicz; Paula L Kosasih; Christoph Rader; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-10-29       Impact factor: 11.151

Review 5.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  CARs in chronic lymphocytic leukemia -- ready to drive.

Authors:  Chitra Hosing; Partow Kebriaei; William Wierda; Bipulendu Jena; Laurence J N Cooper; Elizabeth Shpall
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 7.  Role of memory T cell subsets for adoptive immunotherapy.

Authors:  Dirk H Busch; Simon P Fräßle; Daniel Sommermeyer; Veit R Buchholz; Stanley R Riddell
Journal:  Semin Immunol       Date:  2016-03-11       Impact factor: 11.130

Review 8.  Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

Authors:  Stanley R Riddell; Daniel Sommermeyer; Carolina Berger; Lingfeng Steven Liu; Ashwini Balakrishnan; Alex Salter; Michael Hudecek; David G Maloney; Cameron J Turtle
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360

Review 9.  Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.

Authors:  Partow Kebriaei; Susan S Kelly; Pallavi Manuri; Bipulendu Jena; Rineka Jackson; Elizabeth Shpall; Richard Champlin; Laurence J N Cooper
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

10.  Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques.

Authors:  Carolina Berger; Michael Berger; Brian C Beard; Hans-Peter Kiem; Theodore A Gooley; Stanley R Riddell
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.